GRM5 and fragile X syndrome: Other therapeutic targets have been suggested for FXS on the principle of rebalancing protein synthesis and synaptic function without directly addressing the change in FMR1 (Krueger & Bear, 2011), with mGluR5 being among the most studied (Bear, Huber, & Warren, 2004).